PDCI Presentation at Women In Bio (Montreal Chapter) – April 16th, 2015
The Greater Montreal Chapter of Women In Bio will present a half-day conference followed by a keynote lunch on the latest developments and trends affecting market access ... Read More
10
Apr2015
10
Apr2015
Please be advised that updates to the Manufacturer Submission Policy were published effective April 1, 2015 and can be found at: https://idbl.ab.bluecross.ca/idbl/PDFS/dbl_sec1_drug.pdf
Should Manufacturers require additional clarification regarding the published Manufacturer Submission Policy please contact Alberta Blue Cross, Scientific and Research Services at: submissions@ab.bluecross.ca
For more information, please see ... Read More
07
Apr2015
CADTH has posted its Guidelines for Manufacturers on Application Fees for the CADTH pan-Canadian Oncology Drug Review on its website, after stakeholder comments and feedback were received last month.
Key changes made in response to stakeholders’ comments are detailed in CADTH’s April 1, 2015 notice of implementation.
For ... Read More
30
Mar2015
We recently participated in Mediaplanet Canada’s Rare Diseases campaign in which many industry leaders united to provide Canadians with a comprehensive view of Canada’s healthcare system and the policies that affect the lives of those living with or affected by rare disorders. The campaign was distributed through the National Post on ... Read More
25
Mar2015
Effective April 1, 2015, the pCODR office will be moving to 154 University Avenue, Suite 300, Toronto from its current location at 1 University Ave, Suite 300. This move is to facilitate pCODR’s transition to CADTH while maintaining its central location in downtown Toronto.
Please note the new main telephone and fax ... Read More
12
Mar2015
Category 1 requirements for products that undergo a tailored CDR review have been revised. Submissions for new combination products (funded components) and new combination products designated by CADTH to undergo a tailored CDR review will require completion of the revised New Combination Product Submission Template. This revised template ... Read More
05
Mar2015
CADTH will be implementing an application fee for manufacturer applications filed with the pan-Canadian Oncology Drug Review (pCODR). The proposed fee will apply to all manufacturer applications with a Health Canada Notice of Compliance (NOC) or Notice of Compliance with Conditions (NOC/c) date of April 1, 2015 or later. The ... Read More
23
Feb2015
Effective February 9, 2015 and until this process is transitioned to the pan-Canadian Pharmaceutical Alliance (pCPA) office, Saskatchewan will serve as the single point of entry for the pan-Canadian generic price tier confirmation process. The Saskatchewan Drug Plan will verify that the Tiered Pricing Framework applies to the ... Read More
09
Feb2015
PDCI Market Access Inc. interviewed a representative from one of the pan-Canadian Pharmaceutical Alliance (pCPA) lead provinces and has produced an article providing guidance for negotiating with the pCPA. The pCPA has completed approximately 50 negotiations since it was established in 2010, but stakeholders are still looking for greater transparency ... Read More
04
Feb2015
Pilot Extension for Individual Patient Input to the Common Drug Review
The Common Drug Review (CDR) is extending its pilot to receive patient input submissions from individual patients and caregivers until August 3, 2015.
Pilot Extension for Patient Input for Therapeutic Reviews
CADTH implemented a pilot process for receiving patient input submissions for ... Read More